Johnson & Johnson [JNJ] vs Amgen [AMGN] Detailed Stock Comparison
Johnson & Johnson
NYSE
Loading...
Amgen
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Johnson & Johnson wins in 12 metrics, Amgen wins in 8 metrics, with 0 ties. Johnson & Johnson appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Johnson & Johnson | Amgen | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 17.80 | 27.44 | Johnson & Johnson |
| Price-to-Book Ratio | 5.10 | 26.10 | Johnson & Johnson |
| Debt-to-Equity Ratio | 64.69 | 924.46 | Johnson & Johnson |
| PEG Ratio | 15.68 | 14.58 | Amgen |
| EV/EBITDA | 14.29 | 13.39 | Amgen |
| Profit Margin (TTM) | 25.00% | 17.39% | Johnson & Johnson |
| Operating Margin (TTM) | 28.65% | 28.73% | Amgen |
| EBITDA Margin (TTM) | 28.65% | 28.73% | Amgen |
| Return on Equity | 30.21% | 105.67% | Amgen |
| Return on Assets (TTM) | 7.61% | 7.04% | Johnson & Johnson |
| Free Cash Flow (TTM) | $18.06B | $10.39B | Johnson & Johnson |
| Dividend Yield | 2.47% | 3.20% | Amgen |
| 1-Year Return | 1.90% | -9.77% | Johnson & Johnson |
| Price-to-Sales Ratio (TTM) | 4.42 | 4.75 | Johnson & Johnson |
| Enterprise Value | $432.20B | $210.58B | Johnson & Johnson |
| EV/Revenue Ratio | 4.77 | 6.17 | Johnson & Johnson |
| Gross Profit Margin (TTM) | 67.87% | 63.58% | Johnson & Johnson |
| Revenue per Share (TTM) | $38 | $63 | Amgen |
| Earnings per Share (Diluted) | $9.34 | $10.98 | Amgen |
| Beta (Stock Volatility) | 0.40 | 0.48 | Johnson & Johnson |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Johnson & Johnson vs Amgen Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Johnson & Johnson | -0.51% | -1.09% | 9.50% | 7.01% | 9.41% | 16.14% |
| Amgen | -0.72% | -2.54% | 7.94% | 3.59% | 6.11% | 16.23% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Johnson & Johnson | 1.90% | -2.25% | 12.56% | 69.21% | 178.95% | 163.24% |
| Amgen | -9.77% | 22.38% | 25.21% | 74.90% | 438.74% | 268.02% |
Performance & Financial Health Analysis: Johnson & Johnson vs Amgen
| Metric | JNJ | AMGN |
|---|---|---|
| Market Information | ||
| Market Cap | $400.31B | $162.01B |
| Market Cap Category | Mega cap | Large cap |
| 10 Day Avg. Volume | 9,915,584 | 1,842,602 |
| 90 Day Avg. Volume | 8,799,271 | 2,429,634 |
| Last Close | $167.26 | $301.37 |
| 52 Week Range | $140.68 - $169.99 | $253.30 - $340.89 |
| % from 52W High | -1.61% | -11.59% |
| All-Time High | $186.69 (Apr 25, 2022) | $346.85 (Jul 22, 2024) |
| % from All-Time High | -10.41% | -13.11% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.06% | 0.09% |
| Quarterly Earnings Growth | 0.18% | 0.09% |
| Financial Health | ||
| Profit Margin (TTM) | 0.25% | 0.17% |
| Operating Margin (TTM) | 0.29% | 0.29% |
| Return on Equity (TTM) | 0.30% | 1.06% |
| Debt to Equity (MRQ) | 64.69 | 924.46 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $32.61 | $11.54 |
| Cash per Share (MRQ) | $7.84 | $16.38 |
| Operating Cash Flow (TTM) | $23.03B | $12.19B |
| Levered Free Cash Flow (TTM) | $11.08B | $13.09B |
| Dividends | ||
| Last 12-Month Dividend Yield | 2.47% | 3.20% |
| Last 12-Month Dividend | $3.72 | $9.26 |
Valuation & Enterprise Metrics Analysis: Johnson & Johnson vs Amgen
| Metric | JNJ | AMGN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 17.80 | 27.44 |
| Forward P/E | 15.68 | 14.58 |
| PEG Ratio | 15.68 | 14.58 |
| Price to Sales (TTM) | 4.42 | 4.75 |
| Price to Book (MRQ) | 5.10 | 26.10 |
| Market Capitalization | ||
| Market Capitalization | $400.31B | $162.01B |
| Enterprise Value | $432.20B | $210.58B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.77 | 6.17 |
| Enterprise to EBITDA | 14.29 | 13.39 |
| Risk & Other Metrics | ||
| Beta | 0.40 | 0.48 |
| Book Value per Share (MRQ) | $32.61 | $11.54 |
Financial Statements Comparison: Johnson & Johnson vs Amgen
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | JNJ | AMGN |
|---|---|---|
| Revenue/Sales | $21.89B | $8.15B |
| Cost of Goods Sold | $7.36B | $2.97B |
| Gross Profit | $14.54B | $5.18B |
| Research & Development | $3.23B | $1.49B |
| Operating Income (EBIT) | $6.30B | $1.18B |
| EBITDA | $8.72B | $4.08B |
| Pre-Tax Income | $13.63B | $1.97B |
| Income Tax | $2.63B | $243.00M |
| Net Income (Profit) | $11.00B | $1.73B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | JNJ | AMGN |
|---|---|---|
| Cash & Equivalents | $38.47B | $8.81B |
| Total Current Assets | $71.55B | $26.93B |
| Total Current Liabilities | $56.90B | $23.01B |
| Long-Term Debt | $38.36B | $54.01B |
| Total Shareholders Equity | $78.11B | $6.21B |
| Retained Earnings | N/A | $-27.14B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | JNJ | AMGN |
|---|---|---|
| Operating Cash Flow | $6.35B | $1.71B |
| Capital Expenditures | $-795.00M | $-411.00M |
| Free Cash Flow | $3.37B | $980.00M |
| Debt Repayment | $-2.87B | $-2.50B |
| Common Stock Repurchase | $-2.13B | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | JNJ | AMGN |
|---|---|---|
| Shares Short | 18.27M | 14.70M |
| Short Ratio | 2.21 | 5.46 |
| Short % of Float | 0.01% | 0.03% |
| Average Daily Volume (10 Day) | 9,915,584 | 1,842,602 |
| Average Daily Volume (90 Day) | 8,799,271 | 2,429,634 |
| Shares Outstanding | 2.41B | 537.00M |
| Float Shares | 2.40B | 536.32M |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.74% | 0.84% |
Dividend Analysis & Yield Comparison: Johnson & Johnson vs Amgen
| Metric | JNJ | AMGN |
|---|---|---|
| Last 12-Month Dividend | $3.72 | $9.26 |
| Last 12-Month Dividend Yield | 2.47% | 3.20% |
| 3-Year Avg Annual Dividend | $3.97 | $8.72 |
| 3-Year Avg Dividend Yield | 0.75% | 0.79% |
| 3-Year Total Dividends | $11.92 | $26.16 |
| Ex-Dividend Date | Feb 18, 2025 | May 16, 2025 |